Benitec Biopharma reports FY2026 net loss $45.5M, cash $180.0M; advances BB-301 clinical program

Benitec Biopharma reported a net loss of $45.5 million for the year ended June 30, 2026, compared with a $37.9 million loss the prior year, and held $180.0 million in cash and cash equivalents at year-end. Total operating expenses were $51.2 million, driven by higher R&D and G&A costs, while other…